Global Shingles Vaccine Market 2025–2029: Competitive Insights and Opportunities

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Global Market Value Of The Shingles Vaccine Industry In 2025?

The market for the shingles vaccine has experienced swift expansion over recent years. This market is projected to expand from $4.82 billion in 2024 to $5.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 15.0%. Historically, this expansion has stemmed from factors such as an expanding older demographic, heightened understanding of the advantages of vaccination, improvements in healthcare infrastructure alongside robust immunization initiatives, a greater occurrence of immunocompromised states, and the increased uptake of advanced, more efficacious vaccines.

The shingles vaccine market size is anticipated to experience significant expansion in the coming years, projected to reach $9.58 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 14.6%. This growth during the forecast period is fueled by several factors, including increasing government reimbursement and beneficial pricing policies, a rise in physician recommendations, heightened public health emphasis on adult vaccination, greater investment in research and development alongside product diversification, and improvements in global supply chains and cold-chain capacity. Prominent trends within this period are expected to include advancements in recombinant vaccine technology, progress in adjuvant systems, the integration of shingles vaccination into adult immunization schedules, the incorporation of digital health platforms for vaccine tracking, and innovations in vaccine formulations.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27413&type=smp

What Are The Key Drivers Of Growth In The Shingles Vaccine Market?

A growing number of vaccination initiatives is projected to fuel the expansion of the shingles vaccine market moving forward. These programs are organized public health endeavors designed to systematically administer vaccines to populations to avert the spread of infectious diseases. The increase in vaccination programs stems from greater awareness regarding preventive healthcare, prompting more individuals to seek immunization to avoid illnesses. Vaccination programs boost shingles vaccine adoption by improving public awareness and access, making them highly beneficial for older adults and at-risk groups. They diminish the likelihood of shingles and related complications through the promotion of timely and extensive immunization, thereby enhancing overall community health. For instance, in July 2025, according to the World Health Organization, a Switzerland-based Intergovernmental organization, the coverage for the first dose of human papillomavirus (HPV) vaccine in girls climbed from 27% in 2023 to 31% in 2024. Therefore, the rising incidence of vaccination programs is driving the growth of the shingles vaccine market.

What Are The Different Segment Classifications Within The Shingles Vaccine Market?

The shingles vaccine market covered in this report is segmented

1) By Vaccine Type: Live Attenuated Vaccine, Recombinant Vaccine, Subunit Vaccine

2) By Product: Shingrix, Zostavax, Skyzoster

3) By Age Group: 50-59 Years, 60-69 Years, 70 Years And Above

4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

5) By End User: Hospitals, Clinics, Pharmacies

Subsegments:

1) By Live Attenuated Vaccine: Virus Strain A, Virus Strain B, Virus Strain C

2) By Recombinant Vaccine: Recombinant Protein Vaccine, Recombinant Vector Vaccine, Recombinant Deoxyribonucleic Acid Vaccine

3) By Subunit Vaccine: Protein Subunit Vaccine, Polysaccharide Subunit Vaccine, Conjugate Subunit Vaccine

What Key Innovation Trends Are Fueling Advancements In The Shingles Vaccine Market?

Major companies operating in the shingles vaccine market are prioritizing the creation of innovative vaccine formulations, including recombinant adjuvanted vaccines, to improve immune response and offer long-lasting protection against shingles. Recombinant adjuvanted vaccines function by using laboratory-produced viral proteins alongside substances called adjuvants to amplify the body’s immune response for enhanced and more enduring protection. For instance, in April 2023, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, introduced Shingrix, a shingles vaccine. Shingrix is a non-live, recombinant adjuvanted subunit vaccine administered intramuscularly in two doses for adults aged 50 and above, engineered to prevent shingles (herpes zoster) and its associated complication, post-herpetic neuralgia. This highly effective vaccine delivers over 90% protection against shingles, with robust and sustained immunity lasting a minimum of 10 years, even in older adults and individuals with compromised immune systems.

Which Major Industry Participants Are Leading The Shingles Vaccine Market Growth?

Major companies operating in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/shingles-vaccine-global-market-report

Which Region Is Projected To Lead The Shingles Vaccine Market During The Forecast Period?

North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Shingles Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27413&type=smp

Browse Through More Reports Similar to the Global Shingles Vaccine Market 2025, By The Business Research Company

Construction Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/construction-global-market-report

Folding Furniture Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/folding-furniture-global-market-report

Foldable Houses Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/foldable-houses-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795